Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-08 22:30 |
Monthly information on share capital and company voting rights
|
English | 74.6 KB | ||
| 2020-12-05 23:00 |
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART2…
|
English | 149.9 KB | ||
| 2020-12-05 23:00 |
American Society of Hematology (ASH) : Cellectis dévoile des résultats prélimin…
|
French | 159.5 KB | ||
| 2020-11-18 02:00 |
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candid…
|
English | 94.7 KB | ||
| 2020-11-16 22:30 |
Cellectis Appoints Pharma HR Leader Kyung Nam-Wortman as Executive Vice Preside…
|
English | 94.1 KB | ||
| 2020-11-16 22:30 |
Cellectis nomme Kyung Nam-Wortman, experte de l’industrie pharmaceutique, Vice-…
|
French | 69.9 KB | ||
| 2020-11-06 22:30 |
Monthly information on share capital and company voting rights
|
English | 74.5 KB | ||
| 2020-11-06 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 72.7 KB | ||
| 2020-11-05 22:35 |
Cellectis publie ses résultats financiers pour le troisième trimestre et pour l…
|
French | 299.1 KB | ||
| 2020-11-05 22:34 |
Cellectis Provides Business Update and Reports Financial Results for Third Quar…
|
English | 315.6 KB | ||
| 2020-11-04 15:17 |
American Society of Hematology (ASH) Abstract Shows Initial Anti-Leukemic Activ…
|
English | 183.5 KB | ||
| 2020-10-21 22:30 |
Cellectis to Hold Third Quarter 2020 Earnings Call on Friday, November 6, 2020 …
|
English | 55.5 KB | ||
| 2020-10-21 22:30 |
Cellectis organise une conférence téléphonique pour présenter ses résultats fin…
|
French | 57.9 KB | ||
| 2020-10-16 14:27 |
Calyxt annonce une offre directe enregistrée aux États-Unis de 15 millions de d…
|
French | 182.3 KB | ||
| 2020-10-16 14:25 |
Calyxt Announces $15 Million Registered Direct Offering
|
English | 134.5 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
